Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug.

Of all attempts towards developing a follow on biologics or a biosimilar drug the main detection point stands at the bioequivalence assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable biologics or biosimilars.

 

  • Bioequivalence assessment of respiratory dosage forms
  • Strategies for the bioequivalence assessment of topical dosage forms
  • Bioequivalence approaches for transdermal dosage forms
  • Evaluation of highly variable drugs and drug products

Related Conference of Bioequivalence Assessment

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Bioequivalence Assessment Conference Speakers

Recommended Sessions

Related Journals

Are you interested in